3Q21 results slightly beat; potential re-rating on anti-cycle land acquisitions Slight beat in 3Q21 and guidance maintained China Express Delivery Sector：On-track ASP improvement in Sep；Expect further increase on the back of policy support Significant synergies with the OB/GYN & pediatrics business Pressure mounts after cancelled sale MOLAND： Termination of the consent solicitation Concerns on logistic constraint overdone Morning Research Focus 每日港股简评 Resume coverage; 3Q21 NIM expansion and improving asset quality